Seeing Is Believing
Currently out of the existing stock ratings of Christopher Raymond, 376 are a BUY (80%), 89 are a HOLD (18.94%), 5 are a SELL (1.06%).
Analyst Christopher Raymond, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 49.36% that have a potential upside of 42.72% achieved within 259 days.
Christopher Raymond’s has documented 942 price targets and ratings displayed on 40 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KPTI, Karyopharm Therapeutics at 15-Jan-2025.
Analyst best performing recommendations are on ALXO (ALX ONCOLOGY HOLDINGS ).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 5/31/2018. The price target of $35 was fulfilled within 4 days with a profit of $9.28 (36.08%) receiving and performance score of 90.2.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$220
$49.65 (29.15%)
$209
1 months 13 days ago
(17-Dec-2024)
40/42 (95.24%)
$44.37 (25.26%)
477
Hold
$191
$20.65 (12.12%)
1 months 20 days ago
(10-Dec-2024)
3/4 (75%)
$15.34 (8.73%)
764
Hold
$191
$20.65 (12.12%)
$205
1 months 20 days ago
(10-Dec-2024)
2/4 (50%)
$15.34 (8.73%)
507
Hold
$206
$35.65 (20.93%)
$153
2 months 8 days ago
(22-Nov-2024)
13/14 (92.86%)
$27.92 (15.68%)
293
Buy
$200
$29.65 (17.41%)
$190
2 months 17 days ago
(13-Nov-2024)
12/13 (92.31%)
$28.57 (16.67%)
490
Which stock is Christopher Raymond is most bullish on?
Which stock is Christopher Raymond is most reserved on?
What Year was the first public recommendation made by Christopher Raymond?